We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
The current 0K6R market cap is 9.01B. The company's latest EPS is USD 2.5414 and P/E is 53.29.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 788.09M | 1.05B | 1.13B | 1.49B | 1.89B |
| Operating Income | 72.28M | 163M | 102.5M | 249M | 250.9M |
| Net Income | 37.01M | 407.3M | 89.6M | 154.5M | 249.7M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 1.31B | 1.73B | 2.07B | 2.37B | 3.25B |
| Total Liabilities | 669.12M | 608.5M | 698.5M | 660.9M | 1.02B |
| Total Equity | 636.92M | 1.13B | 1.37B | 1.71B | 2.23B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | 152.05M | 228.5M | 256.5M | 339.4M | 389.9M |
| Investing | -211.07M | 4.1M | -130.2M | -177.1M | -467.1M |
| Financing | 27.31M | -157.8M | 27.4M | -234.3M | 65.3M |
| Market Cap | 9.01B |
| Price to Earnings Ratio | 53.29 |
| Price to Sales Ratio | 7.05 |
| Price to Cash Ratio | 52.99 |
| Price to Book Ratio | 5.96 |
| Dividend Yield | - |
| Shares Outstanding | 98.25M |
| Average Volume (1 week) | 860 |
| Average Volume (1 Month) | 928 |
| 52 Week Change | 0.00% |
| 52 Week High | 91.67 |
| 52 Week Low | 91.67 |
| Spread (Intraday) | 0 (0%) |
| Company Name | Neurocrine Biosciences Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.neurocrine.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
